Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q1 2022 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2021 Net Income-$2.09M-$2.09MN/M vs Q1 2021 EPS Diluted-$0.01-$0.01N/M vs Q1 2021 Operating Income-$1,132,955N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
ended Mar 31, 2022 · filed May 23, 2022 · 53 d after period end